Conditions: Type 2 Diabetes Mellitus
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 60
Healthy volunteers: no

Brief summary:
The purpose of this study is to investigate the safety and effectiveness of the study drug known as LY3053102 in participants with Type 2 diabetes mellitus. The study drug will be given in different doses as an injection under the skin. The study is expected to last up to 6 months for each participant. Participants may remain on stable-dose metformin as prescribed by their personal physician.

Detailed description:

Arms:
arm 1: Stage 1: Escalating dose (7 milligrams \[mg\] up to 200 mg) of LY3053102 administered once a week by subcutaneous (SC) injection for 12 weeks. Stage 2: LY3053102 administered once a week by SC injection for 12 weeks arm 2: Stage 1 and Stage 2: Placebo to match LY3053102 administered by SC injection once a week for 12 weeks arm 3: Stage 1 and Stage 2: Exenatide ER 2 mg given by SC injection once a week for 12 weeks arm 4: Stage 2: LY3053102 administered by SC injection once a week for 12 weeks and exenatide ER 2 mg administered by SC injection once a week for 12 weeks

Interventions: intervention 1: LY3053102 intervention 2: Exenatide ER intervention 3: Placebo intervention 4: Metformin
Intervention descriptions: intervention 1: Administered SC intervention 2: Administered SC intervention 3: Administered SC intervention 4: Administered orally (PO)

Protocol document: